Kinetics of Acute Hepatitis B Virus Infection in Humans

By Simon A. Whalley,* John M. Murray,^{§∥} Dave Brown,* George J.M. Webster,* Vincent C. Emery,[‡] Geoffrey M. Dusheiko,* and Alan S. Perelson[§]

From the *Centre for Hepatology, Department of Medicine, Royal Free Campus, and the [‡]Department of Virology, Royal Free and University College Medical School, London NW3 2QG, United Kingdom; the [§]Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545; and the [§]School of Mathematics, University of New South Wales, Sydney NSW 2052, Australia

Abstract

Using patient data from a unique single source outbreak of hepatitis B virus (HBV) infection, we have characterized the kinetics of acute HBV infection by monitoring viral turnover in the serum during the late incubation and clinical phases of the disease in humans. HBV replicates rapidly with minimally estimated doubling times ranging between 2.2 and 5.8 d (mean 3.7 ± 1.5 d). After a peak viral load in serum of nearly 10^{10} HBV DNA copies/ml is attained, clearance of HBV DNA follows a two or three phase decay pattern with an initial rapid decline characterized by mean half-life ($t_{1/2}$) of 3.7 ± 1.2 d, similar to the $t_{1/2}$ observed in the noncytolytic clearance of covalently closed circular DNA for other hepadnaviruses. The final phase of virion clearance occurs at a variable rate ($t_{1/2}$ of 4.8 to 284 d) and may relate to the rate of loss of infected hepatocytes. Free virus has a mean $t_{1/2}$ of at most 1.2 ± 0.6 d. We estimate a peak HBV production rate of at least 10^{13} virions/day and a maximum production rate of an infected hepatocyte of 200–1,000 virions/day, on average. At this peak rate of virion production we estimate that every possible single and most double mutations would be created each day.

Key words: acute hepatitis B • kinetics • cytotoxic T lymphocytes • mutation • hepatocyte

Introduction

The kinetics of acute hepatitis B virus (HBV)¹ infection have previously been studied in animal models but, until now, there has been limited quantitative data in humans with acute infection (1, 2) and none based on the analytical sensitivity of PCR-based assays. Thus, the quantitation of the kinetics of self-limited acute infection has not been adequately studied. We have recently described a large, common source outbreak of acute hepatitis B, caused by transmission of a single HBV variant by "autohemotherapy". An investigation to identify all cases, to characterize the epidemic, and to limit the transmission of the virus was begun as soon as the first patients were diagnosed. As a result of the early identification of patients infected with HBV in this outbreak, we could analyze data from several patients acutely infected from the same source before symptoms, and seroconversion to anti-HBe, i.e., during both the late incubation and clinical phases of the disease. In this paper, we report on a study of the dynamics of primary HBV infection in humans and estimate rates of viral production and clearance. From serial measurements of serum HBV DNA, we estimate viral doubling times (t_d) and the time between infection and peak viral level. After the peak, viral levels decay in several phases which may correlate with underlying biological mechanisms encompassing decay of covalently closed circular (ccc)DNA, loss of infected hepatocytes, and clearance of free virus.


Materials and Methods

Patients and Data. HBV DNA and alanine transaminase (ALT) levels in serum were obtained for seven patients with primary HBV infection (Fig. 1). ALT was measured by an in-house radioimmunoassay. Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), anti-HBe antibody (anti-HBe), and antibody to hepatitis B core (anti-HBc) status (Fig. 2) were also determined by commercial enzyme immunoassay kits (Abbott Laboratories). Patient 7, who developed chronic hepatitis B infection,

847 The Journal of Experimental Medicine • Volume 193, Number 7, April 2, 2001 847–853 http://www.jem.org/cgi/content/full/193/7/847

Address correspondence to A.S. Perelson, Theoretical Div., MS-K710, Los Alamos National Laboratory, Los Alamos, NM 87545. Phone: 505-667-6829; Fax: 505-665-3493; E-mail: asp@lanl.gov

¹Abbreviations used in this paper: ALT, alanine transaminase; ccc, covalently closed circular; DHBV, duck HBV; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; IS, internal standard.



(2) (6) (3)(7)200 (4) Days HBsAg HBeAg anti⊡HBe anti⊡HBc 100 150 50 200 Davs

(5)

(1)

Figure 2. HBsAg, HBeAg, anti-HBe, and anti-HBc for the seven patients. Black denotes a positive assay, white a negative assay, and gray indicates time between a positive assay and a negative assay.

Figure 1. Serum \log_{10} HBV DNA copies per ml and serum \log_{10} ALT IU/liter values are displayed over the period of observation. In only one patient was there a serious comorbid condition: patient 7 who had cryptogenic organizing pneumonitis for which she was maintained on long-term steroid therapy before her autohemotherapy. Patient 7 failed to clear HBsAg, perhaps because of immunosuppresion, and was commenced on lamivudine 100 mg daily, which is denoted by "L" in the graph. Four patients were identified in the late incubation phase of acute infection when the initial serum HBV DNA was below the eventual peak. t_d for serum HBV DNA were estimated by determining the rise in \log_{10} viral level between the first and second measurements ($\mathbf{\Phi}$). The estimated t_o before peak serum HBV DNA was determined using these t_d .

was identified in the incubation phase of infection and subsequently was commenced on the reverse transcriptase inhibitor lamivudine. We have reported previously that this outbreak of HBV was acquired from contamination of a multidose saline vial used in autohemotherapy (3). Sequencing of HBV DNA, from serum samples obtained at presentation, showed identical nucleotide sequence for the surface and core encoding regions in all of these patients. Thus, all patients were infected with an identical isolate of HBV and had a common source and mode of transmission.

HBV DNA Quantification. Serum samples for HBV DNA quantification were obtained prospectively and stored at -20° C. To reduce interassay variability, all samples derived from each patient were analyzed in the same assay, incorporating up to 41 samples. HBV DNA concentrations in serum were measured by the Amplicor HBV Monitor test (Roche Diagnostics Systems) which is a quantitative PCR based assay and the manufacturer's instructions were followed throughout. In brief, a 104-bp sequence of the precore/core region of HBV is amplified along with an internal standard (IS) to monitor the efficiency of the amplification reaction, one of the primers being biotinylated. Six HBV DNA standards (range 0-10⁶ copies) are amplified at the same time. The amplicons are denatured and the biotinylated strand immobilized on a streptavidin-coated microwell plate. DNP-labeled oligonucleotide probes specific for HBV and the IS are then hybridized to the immobilized amplicons. After washing, the bound probe is quantitated using an ELISA procedure with anti-DNP-alkaline phosphatase conjugate and para-nitrophenylphosphate substrate. Absorbance of sample/HBV probe and sample/IS probe is measured at 405 nm. The HBV to IS signal ratio is calculated to correct for sample to sample differences in amplification efficiency. Finally, the ratios from the unknowns

are compared with a standard curve generated from the HBV standards and the HBV concentrations of each sample are calculated. The assay quantitates virus between 4×10^2 and 4×10^7 particles per ml. Samples exceeding the upper limit were diluted in normal human serum and retested. Comparative quantitation of HBV DNA by this assay have been reported previously (4, 5).

Results

Viral t_d and *Time of Infection*. Patients 1, 2, 5, and 6 were identified in the incubation period when viral levels were below their eventual peak. For each of these patients, the t_d of serum HBV DNA (t_d) was estimated and ranged between 2.2 and 5.8 d with a mean of 3.7 ± 1.5 d. Because data was collected near the peak viral load, the true t_d may have been underestimated.

The time of infection relative to the viral peak, t_0 , was estimated assuming that the infecting inoculum contained 10³ HBV DNA particles (similar to that of a needle stick injury [6]) and distributed throughout 3 liters of serum (Fig. 1). It seemed reasonable to assume that the amount of HBV-contaminated blood introduced into the multidose saline vial used to spread the infection was small because there was no obvious discoloration. This analysis yielded a mean time to infection before the viral peak of 127 ± 46 d. Analyzing the patient with the fastest t_d , patient 2, where we may have caught the earlier stages of viral rise and hence obtained a more accurate estimate of the initial t_{d} , the estimated time until peak virus level after infection was 80 d. This is consistent with the 60–110-d incubation period for the majority of HBV infections in humans (7) and the 8-wk time before viral peak for chimpanzees inoculated with a larger HBV dose (8). Furthermore, in patient 2, the t_{o} was calculated to be around January 29, a date which coincides with her attendance for autohemotherapy on a weekly basis from January 12 to February 16. This provides some validation of our assumption that the infecting inoculum contained $\sim 10^3$ HBV DNA particles, but unfortunately the inoculum was not available for examination and confirmation of the exact HBV content. However, we calculate that each 10-fold error in the initial concentration of HBV would change the estimate of the time from infection to the viral peak by 12.3 d. Because patient 2 could only have been infected while she attended for autohemotherapy, our estimate for her date of infection is at most off by 18 d, and thus the potential miscalculation of the dose is at most by a factor of 10^{1.5}.

Half-Lives of Viral Decay. The decline in serum HBV DNA was multiphasic with an initial rapid decline over several days followed by a slower decline over several weeks. In patients 2 and 6, the transition between these phases was characterized by a rapid fall in viral DNA, which may represent a combination of both phases or a separate biological process. Using linear regression we estimated the rate of viral decay for each dominant phase (Fig. 3), and calculated the corresponding half-lives.

The initial decline in serum viremia was exponential as demonstrated by a straight-line fit to the data on a semilogarithmic plot with a mean R^2 statistic of 0.90 (excluding patient 7 who was on lamivudine therapy). The first phase decay of viral DNA had a mean half-life of 3.7 ± 1.2 d.

The final phase decay of viral DNA had a range of estimated half-lives that varied from 4.8 to 284 d, although we have limited confidence in the long half-life estimates. If we consider only those final phases where the regression lines have an R^2 statistic of 0.8 or better, then the range of half-life values was 4.8 to 17 d with a mean of 12 ± 6 d. This range is consistent with the half-life of infected hepatocytes as estimated using mathematical models in studies of patients chronically infected with HBV treated with lamivudine (half-lives of 10–100 d; reference 9) or adefovir (half-lives of 18 \pm 7 d; reference 10).

(1) (5) R² 0.95 0.98 R² 0.98 0.92 t 1.4 days t_{1/2} 3.4 days 4.8 davs ٥^L 200 200 (2) (6) 10 10 1/2 5 days ¹1/2 4.9 days 0.56 0.97 8 days 284 days 0.02 -0-°° °ò 200 200 (3) (7) H² 0.96 0.3 10 1/2 4.2 days 0.84 34 days 5 42 day 0.36 0 L 0 0 200 50 150 200 100 (4) Davs R2 ¹1/2 3.1 days 0.8 50 100 150 200


Figure 3. Serum HBV DNA half-lives, linear regression lines, and R^2 statistics for the two dominant phases of viral decay for each patient. Endpoints for regression are noted with filled circles.


Days

Free Virus Half-Life. Based on drug perturbation experiments (9, 10) as well as estimates of the half-life of other viruses, the half-life of HBV in serum is expected to be short and clearance of HBV should be the fastest kinetic process that we observe. We thus estimated the half-life of free virus by examining the rate of change of HBV DNA levels between individual data points. We excluded from the calculations patients 3, 4, and 5 because the time between data points was relatively large and would tend to mask the faster half-lives. A histogram of the half-lives in the range 0–6 d is shown in Fig. 4.

The histogram in Fig. 4 displays two clusters of halflives, the shortest between 0.3 and 2.7 d, and the second between 3.7 and 5.8 d. The second cluster is confirmation of the first phase half-life of 3.7 ± 1.2 d discussed above. Under the assumption that the shortest half-lives seen in the data correspond to the decay of free virus (9, 10), we estimated the mean virion half-life by fitting a lognormal distribution to the data in the first cluster (Fig. 4). This gave a mean half-life of free virus of 1.2 ± 0.6 d. The median of this set of half-lives was 1.1 d. This is consistent with the values estimated in treatment studies for chronic HBV showing a free virus half-life of 1.1 d (for adefovir [10]) and 1 d (for lamivudine [9]). As the smallest time between data points was 1 d, there is an inherent bias towards underestimating these decay rates by our method. Consequently, the value derived here provides an underestimate of the decay rate and therefore an overestimate of the halflife. The same caveat can be placed on the literature estimates, where viral levels were measured every 7 d in one study (10), and on days 0, 2, 7, and weekly thereafter in the other (9).

Peak Viral Levels and Rate of Virion Production. For the five patients where the first serum HBV DNA measurement was at or before the peak level, the maximum \log_{10} viral level was determined. The mean maximum \log_{10} viral





level was 9.5 \pm 0.5. The three largest log₁₀ values were 9.8, 9.6, and 10.

A possible explanation for the uniform maximum serum HBV DNA levels seen, and indeed the stable high level for the chronically infected patient 7, is that at the peak of infection nearly all hepatocytes are infected. This would be in agreement with animal studies in which immunohistochemical analysis of liver specimens using antibody directed against the HBV core antigen has shown a >95% infection of hepatocytes in acutely infected woodchucks (11).

If in acute infection most hepatocytes become infected, then we can estimate the daily production of virus by an infected cell. When the peak viral load is reached the amount of virus in the serum is neither increasing nor decreasing so that the infection process is in steady state where the rate of viral production equals the rate of virion clearance. If there are I infected cells, each producing an average of p virions per day, then the rate of virion production is pI. If the peak viral burden is V and free virions are cleared at rate *c* per virion, then the total rate of clearance is cV. The estimated average half-life of free virions of 1.2 d implies that $c = 0.58 \text{ d}^{-1}$. HBV is clearly present in the 3 liters of serum (3 \times 10³ ml) of the prototypical 70-kg person. Its presence in the rest of body water is not well characterized. Thus, we obtain as a minimal estimate that in a person with a peak value of 10^{10} HBV DNA/ml, $V = 3 \times$ 10¹³ virions. If virus is present in all 15 liters of body water at the same concentration as serum, then $V = 15 \times 10^{13}$ virions. Thus, the daily clearance (and daily production at steady state) cV is between 1.7×10^{13} and 8.7×10^{13} virions. If there are 10^{11} hepatocytes in a typical adult liver (12) and 85% are infected, then to attain a peak viral load that is at steady state each infected hepatocyte would need to produce 200-1,000 virions per day. Virions are produced via transcription of cccDNA within the nucleus of infected hepatocytes forming RNA pregenomes that are subsequently reverse transcribed to form the virion HBV DNA (13). If there are 10-50 cccDNA per infected hepatocyte (14), we deduce that each cccDNA gives rise to a daily production of 4-100 new extracellular hepatitis B virions. This deduction does not take into account possible subpopulations of human cccDNA with potentially differing transcriptional activity, as has been reported for duck HBV (DHBV) DNA (15).

Basic Reproductive Number. The basic reproductive number, R_0 , is an estimate of the number of secondary infections that arise from one infected cell over the course of its life span at the beginning of infection when cells susceptible to infection (target cells) are not depleted. If R_0 is >1, then the infection grows, whereas if R_0 is <1 then the infection dies out. From a standard model of viral infection that has been applied to simian immunodeficiency virus (SIV [16]) and HIV (17) infection in which it is a assumed that there is a delay of t days from the infection of a cell to the production of progeny virions, one finds that $R_0 =$ $(1 + r_0/\delta) \exp(r_0 t)$, where r_0 is the initial growth rate of the virus and δ is the loss rate of an infected cell by death or other mechanisms. Using the estimates of the viral t_d given in Fig. 1 we can estimate r_0 , as by definition $t_d = \ln 2/r_0 =$ $0.693/r_0$. If we further assume that the final phase of viral decay reflects the loss of infected cells, then from the halflives reported in Fig. 3 we can estimate δ , as by definition half-life = $0.693/\delta$. For patient 6 the estimate of the final phase half-life is not reliable, but for patients 1, 2, and 5 the R^2 statistic suggests that the estimates shown in Fig. 3 are valid. Computing the R_0 for these patients assuming a 1-d delay between infection and viral production, we find $R_0 =$ 3.1, 7.5, and 4.4, for patients 1, 2, and 5, respectively, with a mean of 5.0. These estimates are most likely underestimates of R_0 , as the number of target cells may have been reduced by the time the patients were first identified and our estimate of r_0 may be an underestimate of the true initial viral growth rate. Patient 2, the patient with the lowest initial viral load and hence the patient for whom the estimate of initial viral growth may be most accurate, has $R_0 =$ 7.5. These estimates suggest that early in acute infection each HBV-infected cell will infect five or more other cells.

Discussion

For patients 1, 2, and 6 (Fig. 1), the initiation of clinical symptoms of acute hepatitis B infection coincided with the peak or the initial decline in serum HBV DNA levels. At this stage, symptoms were mild and consisted only of non-specific lethargy, malaise, myalgia, and headache. By the time jaundice set in, 2–6 wk after the peak in serum HBV DNA, symptoms were deteriorating and viral levels were substantially reduced to $\sim 10^5 - 10^7$ copies/ml.

Interestingly, a faster viral t_d appeared to correlate with the severity of acute infection. Hence, patient 2 with the shortest $t_{\rm d}$ became considerably jaundiced with a serum bilirubin peaking at 847 mmol/ml (normal range 5-17 mmol/ml) and experienced a decline in hepatic synthetic function with a serum albumin of 27 g/liter (normal range 35-50 g/liter) and a prolonged prothrombin time of 24.7 s (normal range <16 s). This was in contrast to patients 1 and 6, with t_d of 3.2 and 3.6 d, respectively, who retained normal hepatic synthetic function though they did become jaundiced with serum bilirubin as high as 429 mmol/ml and 98 mmol/ml, respectively. Patient 5 with the longest t_d of 5.8 d had a relatively mild illness, neither developing jaundice nor impairment of hepatic synthetic function. However, due to the limited sample size, these observations have no statistical power.

In this study we are able to characterize the kinetics of HBV clearance using a quantitative, sensitive assay for HBV DNA. The reason for the rapid first phase $(3.7 \pm 1.2 \text{ d})$ and subsequent phases of viral clearance are, however, unclear from our data. The resolution of acute hepatitis B involves a complex interplay of innate and adaptive immune responses and cellular and humoral immunity. In animal models, it has been suggested that the mechanism underlying initial viral clearance is the noncytopathic removal or inhibition, possibly by cytokines, of cccDNA replenishment (8). In our study, the mean half-life for the first phase of viral clearance is consistent with values obtained in ani-

mal models for the half-life of cccDNA (18, 19). This suggests that the mechanism underlying the first phase of viral decay may indeed be related to clearance of cccDNA; however, we cannot exclude the possibility of inhibition of downstream steps in the viral life cycle, such as viral RNA, but proof of this requires direct experimental evidence. We have not made measurements of intrahepatic replicative intermediates of HBV DNA, nor of intrahepatic cellular immune responses. Thus, the sequential role of innate immunity, cytokine-mediated downregulation of HBV DNA, antigen-specific immune responses, and antibody neutralization can only be speculated on; however, quantitative analysis hints at their importance. The nonspecific symptoms experienced by patients as virus titre starts to fall are similar to those experienced by patients treated with IFN- α , suggesting a role for cytokine-mediated noncytolytic downregulation of the infection. However, proof would require accurate, repeated measurements of cytokines and replicative intermediates of hepatitis B viral DNA within the liver of acutely infected patients, and intrahepatic cytokine concentrations, but these studies, in patients with acute resolving hepatitis B, are ethically inadmissible.

The cccDNA is the transcriptional template for HBV replication (13, 14, 20). The loss of replicative templates thus would be expected to decrease the ability of infected cells to produce hepatitis B virions, and hence serum viral DNA should decrease accordingly. Thus, the administration of a reverse transcriptase inhibitor would abrogate the replenishment of the cccDNA pool, resulting in a decline of serum HBV DNA as cccDNA decays or cells harboring HBV cccDNA die. Patient 7, who remained negative for anti-HBe antibodies, was started on the reverse transcriptase inhibitor lamivudine. In support of the argument that the first phase of viral clearance is due to noncytopathic removal or inhibition of cccDNA replenishment, lamivude treatment resulted in a rate of decline of serum HBV DNA similar to the rate of viral decline observed during the first phase in patients not treated with lamivudine.

HBV is thought to be a noncytopathic virus and that cytotoxic T lymphocytes mediate clearance of HBV-infected cells through a cytolytic process (21, 22). Serum ALT is a surrogate marker of cytolysis of hepatocytes (23, 24). Consistent with the proposed noncytopathic nature of HBV, we observed for patients 2 and 6 that until the peak viral load was reached they remained asymptomatic with normal serum ALT (Fig. 1). For patients 1, 2, 3, 4, and 6, serum ALT peaked at 14 ± 6 d after the peak in serum HBV DNA level. By the time the peak serum ALT was achieved there was at least a one log, that is 90%, fall in the serum HBV DNA level. Therefore, our data suggests that the initial clearance of HBV is a process commenced before the main cytolytic loss of infected hepatocytes. This is in agreement with recent evidence from Guidotti et al. (8) that indicates in the chimpanzee 90% of acutely HBV-infected hepatocytes are cleared of infection by noncytolytic processes.

We have recently studied cellular immune responses in five HLA-A2-positive patients identified in this outbreak, with patients 1 to 5 in the study by Webster et al. (25) cor-

responding to patients 1, 4, 6, 2, and 7, respectively, of this study. Quantification of HBV-specific CD8⁺ cells, in blood, using HLA class I tetramers, suggest that adaptive immune mechanisms are present during the incubation phase, at least 4 wk before symptoms (25). Our results have also suggested that the pattern of reduction in HBV replication is not directly proportional to tissue injury during acute hepatitis B in man (25). As virus-specific immune responses and significant reductions in viral replication are seen during the incubation phase, it is likely that some immunological events central to viral control occur before symptomatic disease. Thus, overall our data are in general agreement that noncytolytic processes may contribute to the initial control of the virus but mechanisms involving cytolysis are also involved at this early stage. It is of note that in each of the patients that we studied, the initial fall from peak viral load was associated with some elevation of ALT. However, given that the peak ALT occurred 14 ± 6 d after the peak in serum HBV DNA level, the cytolytic mechanisms of viral clearance may take longer to initiate than noncytolytic mechanisms and may play a greater role once there has been a substantial fall in the serum viral load. After the initial decline in serum HBV levels, there appears to be a slower final phase of viral clearance characterized in a subset of patients by a half-life of 12 ± 6 d, that coincides with previous estimates of the rate of removal by the immune system of infected hepatocytes (9, 10). The fact that serum aminotransferases are raised during this phase suggests that the latter phase may be related to death of hepatocytes by apoptosis and hepatocellular necrosis.

Antibodies to pre-S1 appear early in acute hepatitis B and may be important in elimination of viremia (26). We have not examined whether one of the phases of viral clearance (perhaps by the inhibition of HBV attachment to a hepatocyte receptor or the regulation of intrahepatic DNA levels and viral assembly) could be due to pre-S1 antibody. The pre-S1 protein (large HBsAg protein) is an essential component of the envelope of HBV virions, but is also found, although in far smaller amounts, on HBV tubular filaments (but not on 20-nm circular particles [27]). We have no measure of the relative proportions of mature virions to filaments in plasma during the phases of acute hepatitis B, nor of antigen antibody complexing of anti-pre-S1 to expressed pre-S1, which if present could potentially limit the usefulness of anti-pre-S1 measurements. However, recently a good correlation was observed between pre-S1 antigen measured by enzyme-linked immunoassay, and HBV DNA measured by the Roche Amplicor assay (28). Thus, we believe that our measurements of viral kinetics are valid, but careful quantitation of pre-S1 antigen, antibody, and intracellular HBV DNA in animal models could shed further light on mechanisms of viral clearance in future studies.

Using a unique cohort of primary HBV-infected patients, we have characterized the early kinetics of HBV infection, during the late incubation phase and early clinical period of acute hepatitis B. We have shown that HBV can double as rapidly as every 2.2 d leading to the creation of viral loads that peak near 10^{10} HBV DNA copies (or particles)/ml at times as early as 80 d after infection. Our analysis suggests that even though extremely high serum viral loads are attained, if the vast majority of hepatocytes become productively infected then each cell need only produce 200–1,000 virions per day at the peak of infection. However, as noncytolytic processes diminish cccDNA, we would predict the virion production rate to drop dramatically. Although the virion production rate in infected humans is not known, Lin et al. (29) have shown that in DHBV infection the total DNA load in the liver is \sim 500 copies per cell, which although it includes the DHBV cccDNA, is in the range that we predict for humans during acute infection.

Variability in HBV t_d was observed among patients, even though the patients were infected from the same source. More rapid daily replication of HBV appeared to be associated with an increase in severity of acute hepatitis, suggesting that host factors play an important role in determining both HBV dynamics and the severity of subsequent liver disease.

From the estimated HBV t_d and the half-life estimates of productively infected cells obtained from an examination of the final phase of viral decay, we were able to obtain the first estimates of the R_0 for HBV. This number indicates how many cells are infected by the progeny virions produced by an infected cell early in acute infection, i.e., before target cells are depleted. For the three patients for whom we could do this analysis, R_0 ranged between 3.1 and 7.4 with a mean of 5. In HIV infection, R_0 has been estimated as 19.3 (17). Any intervention that reduces R_0 below 1 results in fewer than one secondary infected cell arising from each initial infected cell. Thus, the size of R_0 provides an estimate of how difficult it should be to extinguish infection via therapy, vaccination, or host response. The most accurate estimates of the R_0 are when target cells are unlimited. It is therefore likely that the estimates here are a small underestimate of the true R_0 , as target cells are likely to be depleted during the course of acute hepatitis B infection. However, in keeping with other studies, such as those for acute HIV infection, it is unlikely that this underestimate will substantially increase the value of R_0 (17). The significantly smaller R_0 that we report for HBV compared with that of HIV is in agreement with the observation that the vast majority of immunocompetent adults that are infected with HBV never develop chronic infection (30) and the efficacy of HBV vaccination (31).

If R_0 can be reduced below 1, say by vaccination, then infection should die out. However, bile duct cells and extrahepatic compartments may be a reservoir for hepadnaviruses that may harbor virus for long periods, although, at present, it would appear that in humans, the major burden of HBV replication occurs in the hepatic compartment (29).

Each virion undergoes reverse transcription before its expulsion from an infected cell. As HBV reverse transcriptase contains no error correction mechanism, this is an inherently error-prone process. The in vivo HIV error rate for reverse transcription is estimated as 3.4×10^{-5} base

Table I. Rate of Generation of HBV Mutants at Peak Infection

Base changes	Fraction	No. created per day	No. of possible mutants*	Fraction of all possible mutants created per day
0	0.9968	9.97×10^{12}	_	_
1	0.0032	3.2×10^{10}	9.6×10^{3}	1
2	5×10^{-6}	5×10^7	4.6×10^{7}	0.66
3	5.4×10^{-9}	5.4×10^{4}	1.5×10^{11}	3.6×10^{-7}

*Computed as $3^{i}\binom{n}{i}$ where n = 3,200 is the genome length, *i* is the number of base changes, and $\binom{n}{i}$ is a binomial coefficient.

substitutions per site per replication cycle (32). If we assume conservatively that the error rate for HBV to be lower at say 10⁻⁶ base substitutions per site per reverse transcription then we can estimate the likely number of virions that contain mutations from wild-type. With 3,200 bases in the HBV genome, the average number of base changes is 0.0032 per reverse transcription and hence per virion. According to the Poisson distribution, we thus expect $\sim 0.32\%$ of new virions to have a single mutation. Our calculations show that $>10^{13}$ virions are produced daily and observed in the blood at peak infection. Therefore, we would expect at least 3.2×10^{10} point mutations to be produced per day, vastly more than the possible number of different single base changes in the HBV genome (Table I). Hence, we would expect all possible single base changes to be produced per day at peak infection. The calculations in Table I show that this is also true for the majority of double mutations. This has important consequences for the development of mutations that escape the immune response, and also for mutations that provide resistance to reverse transcriptase inhibitors.

Further characterization of the kinetics of acute HBV infection should lead to better understanding of the biological processes underlying the virological, immunological, and liver pathological aspects of the resulting hepatitis.

We thank Dr. F. Mattes for assistance with the serological data and Dr. G. Colucci, at Roche (Basel, Switzerland) for providing the Amplicor Monitor test kits.

Portions of this work were done under the auspices of the U.S. Department of Energy. This work was funded in part by National Institutes of Health grant RR06555 and the Peter Samuel Research Fund.

Submitted: 11 October 2000 Accepted: 26 February 2001

References

- 1. Fong, T.L., E.A. Akriviadis, S. Govindarajan, B. Valinluck, and A.G. Redeker. 1989. Serum hepatitis B viral DNA in acute viral hepatitis B. *Ann. Intern. Med.* 110:936–937.
- 2. Fong, T.L., A.M. Di Bisceglie, R. Biswas, J.G. Waggoner, L.

Wilson, J. Claggett, and J.H. Hoofnagle. 1994. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. *J. Med. Virol.* 43:155–158.

- Webster, G.J., R. Hallett, S.A. Whalley, M. Meltzer, K. Balogun, D. Brown, C.P. Farrington, S. Sharma, G. Hamilton, S.C. Farrow, et al. 2000. The molecular epidemiology of a large outbreak of hepatitis B linked to 'autohaemotherapy'. *Lancet.* 356:379–384.
- Pawlotsky, J.M., A. Bastle, C. Hezode, I. Lonjon, F. Darthuy, J. Remine, and D. Dhumeaux. 2000. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories. J. Immunol. Methods. 85:11–21.
- Noborg, U., A. Gusdal, E.K. Pisa, A. Hedrum, and M. Lindh. 1999. Automated quantitative analysis of hepatitis B virus DNA by using the cobra Amplicor HBV monitor test. *J. Clin. Microbiol.* 37:2793–2797.
- Jilbert, A.R., D.S. Miller, C.A. Scougall, H. Turnbull, and C.J. Burrell. 1996. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. *Virology*. 226:338– 345.
- McIntyre, N. 1990. Clinical presentation of acute viral hepatitis. Br. Med. Bull. 46:533–547.
- Guidotti, L.G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F.V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. *Science*. 284:825–829.
- Nowak, M.A., S. Bonhoeffer, A.M. Hill, R. Boehme, H.C. Thomas, and H. McDade. 1996. Viral dynamics in hepatitis B virus infection. *Proc. Natl. Acad. Sci. USA*. 93:4398–4402.
- Tsiang, M., J.F. Rooney, J.J. Toole, and C.S. Gibbs. 1999. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. *Hepatology*. 29:1863–1869.
- Guo, J.T., H. Zhou, C. Liu, C. Aldrich, J. Saputelli, T. Whitaker, M.I. Barrasa, W.S. Mason, and C. Seeger. 2000. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J. Virol. 74:1495–1505.
- Sherlock, S.D., and J. Dooley. 1996. Diseases of the Liver and Biliary System. 10th ed. Blackwell Science Ltd., London, England. 714 pp.
- Mason, W.S., M.S. Halpern, J.M. England, G. Seal, J. Egan, L. Coates, C. Aldrich, and J. Summers. 1983. Experimental transmission of duck hepatitis B virus. *Virology*. 131:375–384.
- Tuttleman, J.S., C. Pourcel, and J. Summers. 1986. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. *Cell*. 47:451–460.
- Newbold, J.E., H. Xin, M. Tenca, G. Sherman, J. Dean, S. Bowden, and S. Locarnini. 1995. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. *J. Virol.* 69:3350–3357.
- Nowak, M.A., A.L. Lloyd, G.M. Vasquez, T.A. Wiltrout, L.M. Wahl, N. Bischofberger, J. Williams, A. Kinter, A.S. Fauci, V.M. Hirsch, and J.D. Lifson. 1997. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71:7518–7525.
- Little, S.J., A.R. McLean, C.A. Spina, D.D. Richman, and D.V. Havlir. 1999. Viral dynamics of acute HIV-1 infection. *J. Exp. Med.* 190:841–850.
- 18. Civitico, G.M. and S.A. Locarnini. 1994. The half-life of

duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. *Virology*. 203:81–89.

- Delaney, W.E., T.G. Miller, and H.C. Isom. 1999. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. *Antimicrob. Agents Chemother*. 43:2017–2026.
- Summers, J., and W.S. Mason. 1982. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. *Cell*. 29:403–415.
- 21. Mondelli, M., G.M. Vergani, A. Alberti, D. Vergani, B. Portmann, A.L. Eddleston, and R. Williams. 1982. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J. Immunol. 129:2773–2778.
- 22. Chisari, F.V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29-60.
- Feutren, G., B. Lacour, and J.F. Bach. 1984. Immune lysis of hepatocytes in culture: accurate detection by aspartate aminotransferase release measurement. J. Immunol. Methods. 75: 85–94.
- Kew, M.C. 2000. Serum aminotransferase concentration as evidence of hepatocellular damage. *Lancet*. 355:591–592.
- Webster, G.J.M., S. Reignat, M.K. Maini, S.A. Whalley, G.S. Ogg, A. King, D. Brown, P.L. Amlot, R. Williams, D. Vergani, et al. 2000. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. *Hepatology*. 32:1117–1124.
- 26. Gerken, G., M. Manns, W.H. Gerlich, G. Hess, and K.-H. Meyer zum Buschenfelde. 1987. Pre-S encoded surface proteins in relation to the major viral surface antigen in acute hepatitis B virus infection. *Gastroenterology*. 92:1864–1868.
- Heermann, K.H., U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten, and W. Gerlich. 1984. Large surface proteins of hepatitis B virus containing the pre-S sequence. *J. Virol.* 52:396–402.
- 28. Buffello-Le Guillou, D., J.C. Duclos-Vallee, F. Eberle, F. Capel, and M.A. Petif 2000. Evaluation of an enzyme linked immunosorbent assay for detection and quantification of hepatitis B virus preS1 envelope antigen in serum samples: comparison with two commercial assays for measuring hepatitis B virus DNA. *Viral Hepatitis*. 7:387–392.
- Lin, E., C. Luscombe, Y.Y. Wang, T. Shaw, and S. Locarnini. 1996. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B infection in vivo. *Antimicrob. Agents Chemother.* 40:413–418.
- Hymans, K.C. 1995. Risks of chronicity following acute hepatitis B virus infection: a review. *Clin. Infect. Dis.* 20:992– 1000.
- Szmuness, W., C.E. Stevens, E.A. Zang, E.J. Harley, and A. Kellner. 1981. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. *Hepatology*. 1:377–385.
- 32. Mansky, L.M., and H.M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087–5094.